Semaglutide vs. Tirzepatide: How Doctors Decide
Not which is "better" — but how clinicians choose between them for specific patients.
Semaglutide (Wegovy) and tirzepatide (Zepbound) are the two dominant GLP-1-based weight loss medications. They're similar enough to confuse — both are weekly injections, both cause significant weight loss, both come from pharmaceutical giants. But they work differently at the molecular level, and those differences create distinct clinical profiles that inform prescribing decisions.
This article isn't about declaring a winner. It's about understanding the factors that lead a physician to recommend one over the other for a specific patient.
How They Work: The Mechanism Difference
Activates only the GLP-1 receptor. Slows gastric emptying, reduces appetite by signaling satiety to the hypothalamus, and improves insulin sensitivity. The mechanism is well-studied with years of post-market data from its earlier diabetes indication (Ozempic).
Activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The GIP component appears to work synergistically — enhancing appetite suppression, improving insulin sensitivity in adipose tissue, and potentially improving tolerability by reducing nausea through central brain pathways.
The Trial Data: Head to Head
The question of comparative efficacy was settled in 2025 when the SURMOUNT-5 trial directly compared tirzepatide and semaglutide head-to-head for the first time:
Tirzepatide demonstrated statistically superior weight loss — approximately 47% more relative weight loss than semaglutide. Notably, the GI side effect rates were similar between the two drugs, challenging the assumption that more efficacy necessarily means more nausea.
How Doctors Choose: The Decision Factors
Insurance and Access
In practice, this is often the deciding factor. Semaglutide (Wegovy) has been on the market longer and has broader insurance formulary coverage. Many insurers require "step therapy" — meaning you must try and fail semaglutide before they'll approve tirzepatide. If your insurance covers one but not the other, the decision is often made for you.
Weight Loss Goals
For patients who need to lose more than 15% of body weight — especially those with BMI over 40 or obesity-related complications that would benefit from dramatic weight reduction — tirzepatide's superior efficacy data makes it the stronger clinical argument. For patients who need more moderate weight loss (10–15%), semaglutide may be sufficient and more easily accessible.
Diabetes Status
Both medications are effective for Type 2 diabetes management. However, tirzepatide's dual mechanism shows particularly strong A1C reduction and insulin sensitivity improvement. For patients with Type 2 diabetes who also need weight loss, tirzepatide's metabolic profile is compelling.
Prior Treatment Response
Patients who have plateaued on semaglutide at the maximum dose are common candidates for switching to tirzepatide. The different mechanism offers a new pathway that can break through a stall. This is sometimes called the "plateau shift" strategy.
Nausea Tolerance
Despite similar overall GI side effect rates in trials, the subjective experience varies. Some patients who couldn't tolerate semaglutide find tirzepatide more manageable (or vice versa). The GIP component in tirzepatide may modulate nausea through central pathways, though individual responses differ significantly.
Cost (Cash Pay)
For patients paying out of pocket through compounding pharmacies, the price difference is a factor. Compounded semaglutide is generally cheaper and more widely available than compounded tirzepatide, partly because semaglutide has been compounded for longer and the supply chain is more mature. This gap is narrowing but remains relevant for many cash-pay patients.
Many prescribing decisions come down to access, not pharmacology. The "best" medication is the one your patient can actually obtain, afford, and stay on consistently. A prescription that sits unfilled because of cost or insurance barriers helps nobody.
Providers offering both semaglutide and tirzepatide programs.
Affiliate links. We earn commission at no cost to you.
The Bottom Line
Tirzepatide produces more weight loss in clinical trials. Semaglutide has broader insurance coverage and a longer track record. Your doctor should factor in your weight loss goals, diabetes status, insurance situation, cost tolerance, and prior treatment history — not just pick the one with the bigger number. Ask your provider why they're recommending one over the other, and make sure the answer accounts for your specific clinical picture.